Skip to content
‹ Back to IndustriesHealthcare

How Hospitals Can Adapt to Supply Chain Disruptions

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard. In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains. In uncertain periods such as this,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
How Hospitals Can Adapt to Supply Chain Disruptions

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard.

In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains.

In uncertain periods such as this, TPC stands ready to assist its Member hospitals in finding agile solutions to these disruptions that allow operations to remain as close to normal as possible as we collectively work through the challenges set in front of us.

As COVID-19 Proves, Healthcare Providers Must Be Ready to Pivot at a Moment’s Notice

Though COVID-19 is far from the first disruptive force healthcare supply chains have been asked to navigate, it has presented some unique challenges.

It’s more important than ever to evaluate best practices in adapting and responding to these disruptions.

First, it’s critical to thoroughly review not only your own supply chain, but the state of key drugs, other products, and their manufacturers. The FDA has been diligent in working with manufacturers of both drugs and medical equipment to get an idea of exactly how disruptive this pandemic might be, and it’s important that you leverage that information as often as you can to formulate a plan of attack that addresses potential impacts on your own supply chain.

Proactive risk management plans, data sharing and collaboration can ensure you’re firmly on the front line in fighting these disruptions and continuing to provide the key services and quality care for your patients.

Several best practices have also been recommended during this pandemic, including:

  • Providing education regarding COVID-19 to staff.
  • Rationing masks and personal protective equipment and curtailing areas where these products are available for use.
  • Managing N-95 mask usage and creating a proactive plan regarding nurses who will use the masks, careful attention to reuse guidelines, and more.

TPC is Proud to Help Guide You Through Uncertainty

As uncertainty mounts in the face of these supply chain disruptions, TPC is, as always, committed to acting as your guide toward proactive, beneficial action and working to source new suppliers and evaluate innovative solutions to assist our Members in their time of need.

With TPC’s ongoing commitment to communication and support, you can be confident in your ability to navigate these temporary disruptions and continue providing the best possible care to your patients.

Disruptions are going to occur, and COVID-19 is far from the last – however, by being flexible in addressing these challenges, we can work together to find solutions, providing valuable support within the TPC Member family.

To learn more or reach out with any specific questions, visit tpc1.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512